This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
It has been about a month since the last earnings report for TCF Financial Corporation (TCF - Free Report) . Shares have added about 8.8% in that time frame.
TCB TCB.PRC TCB.PRB TCB-B TCF TCB.WS TCF.PRC TCF.PRD TCB-C UTX TCF.WS CR
On May 7, we issued an updated research report on TCF Financial Corporation (TCF - Free Report) . The company’s digitization efforts to meet customer requirements and solid organic growth indicate its upside potential. However, escalating expenses and declining fee income remain concerns.
TCB TCB.PRC TCB.PRB TCB-B TCF TCB.WS LAZ TCF.PRC TCF.PRD TCB-C TCF.WS CFR
TCF produced strong year-over-year revenue, earnings, and loan growth in a relatively more challenging quarter for many peer banks.
WFCNP TCB TCB.PRC TCB.PRB TCF WFC.PRL TCF.PRC TCF.PRD WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ TCB-B WFC.PRP WFC.PRO WFC.PRN TCB-C WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS CMA TCB.WS PNC TCF.WS
Shares of TCF Financial Corporation (TCF - Free Report) climbed 7.27% in single-day trading following the first-quarter 2018 earnings release on Apr 23, before the market opened. The company reported earnings per share of 39 cents, beating the Zacks Consensus Estimate of 37 cents. Further, the figure compared favorably with the prior-year quarter figure of 25 cents. Notably, results include non-recurring items of 2 cents per share associated with the redemption of perpetual preferred stock.
TCB TCB.PRC TCB.PRB TCF TCBI TCBIL TCF.PRC TCF.PRD TCBIW TCB-B TCB.WS TCBIP TCB-C TCF.WS
TCF Financial Corporation (NYSE:TCF) Q1 2018 Results Earnings Conference Call April 23, 2018 10:00 AM ET
WFCNP TCB TCB.PRC TCB.PRB DB TCF WFC.PRL TCF.PRC TCF.PRD WFC.PRJ WFC.PRT WFC.PRR WFC.PRQ TCB-B WFC.PRP WFC.PRO WFC.PRN TCB-C WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS TCB.WS TCF.WS
Performances of most of the banks that released their first-quarter 2018 results till now were decent. Driven by higher rates and modest improvement in loan balances, banks reported an increase in their net interest income. Also, given the rebound in trading activities during the quarter, trading revenues improved. However, lower mortgage income and dismal investment banking performance adversely impacted overall fee income to some extent.
TCB TCB.PRC ZIONW TCB.PRB TCF BOH TCF.PRC TCF.PRD ZB.PRF ZB.PRA ZBK ZION ZB.PRG TCB-B ZB.PRH TCB.WS TCB-C TCF.WS ONB ZIONZ
With strong fundamentals and organic growth prospects, First Financial Bancorp. (FFBC - Free Report) appears to be an attractive pick now. In addition, interest rate hikes and improving economy are anticipated to further improve profitability. Analysts seem to be optimistic about the company’s prospects as the stock is witnessing upward estimate revisions. Over the past 60 days, the Zacks Consensus Estimate for the current year has risen nearly 1.
TCB TCB.PRC TCB.PRB TCF TCF.PRC FFBC TCF.PRD PRK FFBCW HTLF TCB-B TCB.WS VIRT THFF TCB-C TCF.WS
Fifth Third Bancorp (FITB - Free Report) is a promising stock now due to its diligent efforts to enhance profitability through Project North Star initiatives. Also, the company’s organic and inorganic growth strategies make it well poised for future endeavors. Further, earnings growth prospects and favorable valuation make it an attractive pick.
TCB TCB.PRC TCB.PRB CMA.WS CMA TCF TCF.PRC TCF.PRD FITBI CMPWW TCB-B TCB.WS VIRT FITB TCB-C TCF.WS
The U.S. banking sector has been the center of attraction for quite some time now due to the favorable turn of events since Trump took office. Moreover, continual rise in interest rates and lower commercial tax rate are likely to further boost profitability of the banks.
TCB HBANN TCB.PRC HBANO TCB.PRB HBANP TCF TCF.PRC TCF.PRD HBAN TCB-B TCB.WS MYGN TCB-C TCF.WS
A probe by the Manhattan district attorney into Newsweek Media Group, including its ad practices and loans, has widened to look at ties to a California bible college.
TCB HBANN TCB.PRC HBANO TCB.PRB HBANP TCF TCF.PRC TCF.PRD WTFCW WTFPP WTFC HBAN WTFCM TCB-B TCB.WS TCB-C TCF.WS
1h - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
2018-07-13 - Asif
Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...
2018-07-09 - Asif
Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...
Silicon Investor Message Boards
This table lists all message boards related to TCF / TCF Financial Corporation on message board site Silicon Investor.
|Current Tech CRTCF||Vanteck (vrb-cdnx, vttcf)|
|Fruehauf FTCFQ||TCFG 21ST CENTURY FRONTIER GRP INC|
|TCB -- TCF Financial||FTCFQ (Freuhauf) = No Money!|
as of ET